Intermittent high-dose treatment with erlotinib enhances therapeutic efficacy in EGFR-mutant lung cancer.
Schöttle J, Chatterjee S, Volz C, Siobal M, Florin A, Rokitta D, Hinze Y, Dietlein F, Plenker D, König K, Albus K, Heuckmann JM, Rauh D, Franz T, Neumaier B, Fuhr U, Heukamp LC, Ullrich RT.
Schöttle J, et al. Among authors: hinze y.
Oncotarget. 2015 Nov 17;6(36):38458-68. doi: 10.18632/oncotarget.6276.
Oncotarget. 2015.
PMID: 26540572
Free PMC article.